Last checked at 
LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday said the European Patent Office has granted a technology patent relating to its microcrystalline tyrosine depot adjuvant manufacturing process.
The drug developer focused on allergy vaccines said the patent covers the manufacture and physiochemical characteristics of microcrystalline tyrosine in combination with one of more anitgens.
Allergy said the granting of the patent further strengthens its Bencard Adjuvant Systems division, which specialises in developing and optimising aluminium-free adjuvants for infectious diseases. Recent data has shown that coupling microcrystalline tyrosine with another adjuvant from its Bencard Adjuvant Systems has a synergistic effect.
The adjuvant system created through the coupling, AdSys-VcT, demonstrated protective efficacy in a malaria model in a study undertaken in collaboration with the University of Oxford, Allergy Therapeutics said.
"We are pleased to expand this key patent and are excited by the potential for microcrystalline tyrosine as a core technology within our adjuvant portfolio to create novel and efficacious vaccines, both in allergies and also in infectious disease areas such as malaria and influenza," said Chief Executive Manuel Llobet.
"This further underpins the future pipeline for products, and the long term success of Allergy Therapeutics to continue innovating and producing novel medicines," Llobet added.
Shares in Allergy Therapeutics were up 5.2% at 23.40 pence on Wednesday morning.
By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.
